Overall the present results suggest that it is now viable to routinely compare numerous Markov State Models to assess the effects of ligand binding or point mutations on protein function. Extension of the present sMD/MSM methodology to other drug target classes is warranted to validate the generality of the approach for supporting allosteric drug design workflows.